Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Q32 Bio (QTTB) over the last 9 years, with Q3 2025 value amounting to $1.2 million.

  • Q32 Bio's Share-based Compensation fell 1490.59% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 3777.35%. This contributed to the annual value of $4.4 million for FY2024, which is 20714.29% up from last year.
  • According to the latest figures from Q3 2025, Q32 Bio's Share-based Compensation is $1.2 million, which was down 1490.59% from $1.3 million recorded in Q2 2025.
  • Q32 Bio's Share-based Compensation's 5-year high stood at $4.7 million during Q4 2021, with a 5-year trough of $296000.0 in Q1 2023.
  • For the 5-year period, Q32 Bio's Share-based Compensation averaged around $2.1 million, with its median value being $1.3 million (2025).
  • In the last 5 years, Q32 Bio's Share-based Compensation tumbled by 9269.32% in 2023 and then surged by 35913.62% in 2024.
  • Quarter analysis of 5 years shows Q32 Bio's Share-based Compensation stood at $4.7 million in 2021, then crashed by 33.76% to $3.1 million in 2022, then tumbled by 83.13% to $521000.0 in 2023, then soared by 140.12% to $1.3 million in 2024, then decreased by 6.0% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.3 million for Q2 2025, and $1.3 million during Q1 2025.